Top Suppliers:I want be here
Related CAS#:
144701-48-4 1189889-44-8
23031-25-6 915124-86-6
515815-47-1 1261396-33-1
1098100-86-7 144702-26-1
144702-27-2 1026353-20-7
1158522-08-7 1379161-23-5
940364-43-2 1183931-13-6
134104-43-1 131615-57-1
6906-52-1 930439-75-1
1018584-77-4 1375289-11-4

144701-48-4

144701-48-4 structure
144701-48-4 structure
  • Name: Telmisartan
  • Chemical Name: telmisartan
  • CAS Number: 144701-48-4
  • Molecular Formula: C33H30N4O2
  • Molecular Weight: 514.617
  • Catalog: API Circulatory system medication Antihypertensive drug
  • Create Date: 2018-02-07 08:00:00
  • Modify Date: 2024-01-02 16:10:35
  • Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
Name telmisartan
Synonyms Kinzalmono
Micardis
4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid
MFCD00929085
4'-[(1,7'-Dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]-2-biphenylcarboxylic acid
[1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]-
Pritor
Telmisartan
EINECS 620-494-7
Description Telmisartan is a potent, long lasting antagonist of angiotensin II type 1 receptor (AT1), selectively inhibiting the binding of 125I-AngII to AT1 receptors with IC50 of 9.2 nM.
Related Catalog
Target

IC50: 9.2 nM (angiotensin II type 1 receptor)[1]

In Vitro In intact RVSMC cells and in membrane preparations, telmisartan inhibits the binding of 125I-AngII to AT1 receptors in a concentration-dependent manner, with an IC50 of 9.2 ± 0.8 nM. In the same experimental conditions, angiotensin II displaces 125I-AngII with an IC50 value of 2.9 ± 0.5 nM. The specific binding of [3H]telmisartan to SMC membranes is displaced by unlabeled telmisartan with an IC50 of 7.7 ± 1.8 nM and by cold AngII with an IC50 of 32.7 ± 5.7 nM [1]. Telmisartan treatment (100 μM) reduces the proliferation of three EAC cell lines (OE19, OE33, and SKGT-4), induces cell cycle arrest in G0/G1 phase and regulates cell cycle-related proteins in EAC cells, and induces the phosphorylation of AMPK and regulates cell cycle-related proteins via the AMPK/mTOR pathway in EAC cells. Telmisartan inhibits the activation of RTKs, downstream effectors and cell cycle-related proteins[5].
In Vivo In the telmisartan (0.1, 0.3, and 1 mg/kg)-treated rats, the specific binding of [3H]telmisartan to the surface of living RVSMC is saturable and increases quickly to reach equilibrium within 1 h. Telmisartan dissociates very slowly from the receptor with a dissociation half-life (t1/2) of 75 min, which is comparable with candesartan and almost 5 times slower than angiotensin II (AngII). In vivo, telmisartan blunts the blood pressure response to exogenous AngII dose dependently[1]. Telmisartan (10 mg/kg/d) administration effectively suppresses aneurysm pathogenesis after PPE infusion as well, regardless of whether treatment is initiated before or after aneurysm creation or continues for a limited or extended time. Telmisartan treatment is associated with reduced messenger RNA levels for CCL5 and matrix metalloproteinases 2 and 9 in aneurysmal aortae, with no apparent effect on PPARγ-regulated gene expression[2]. Telmisartan (1 mg/kg/day) significantly ameliorates neuronal loss and the spatial acquisition impairment in 5XFAD mice, but without any changes of NeuN expression in the hippocampus layer. Telmisartan (1 mg/kg/day) treatment reduces amyloid burden and microglial accumulation in 5XFAD mice brain, induces microglial polarization towards neuroprotective phenotype, but does not alter the expression levels of NEP and IDE in 5XFAD mice specific brain areas[3]. Telmisartan (0.05, 0.1, 1 mg/kg, p.o.) shows significant reduction in immobility time, antagonizes depression and anxiety, and also significantly attenuates serum cortisol, NO, IL-6 and IL-1β in rats[4]. Telmisartan (50 μg, i.p.) leads to a 73.2% reduction in tumor growth in mice bearing xenografts derived from OE19 cells. Furthermore, miRNA expression is significantly altered by telmisartan in vivo[5].
Cell Assay Cell proliferation is assayed using the CCK-8 cell counting kit. Briefly, 5×103 cells are seeded into each well of a 96-well plate and cultured in 100 μL of RPMI-1640 supplemented with 10% FBS. After 24 h, ARBs (telmisartan, irbesartan, losartan, and valsartan at 0, 1, 10, or 100 μM) or vehicle is added to each well, and cells are cultured for an additional 48 h. CCK-8 reagent (10 μL) is added to each well, and the plates are incubated at 37°C for 3 h. The absorbance is measured at 450 nm using a microplate reader.
Animal Admin Male athymic mice (BALB/c-nu/nu; 6 weeks old; 20-25 g) are maintained under specific pathogen-free conditions using a laminar airflow rack. The mice have continuous free access to sterilized (γ-irradiated) food and autoclaved water. Each mouse is subcutaneously inoculated with OE19 cells (5×106 cells per animal) in the flank. One week later, the xenografts are identifiable as masses with a maximal diameter > 4 mm. The animals are randomly assigned to treatment with telmisartan (50 μg per day) or diluent only (control). The telmisartan group is intraperitoneally (i.p.) injected five times per week with 2 mg/kg telmisartan for four weeks; the control group is administered 5% DMSO alone for four weeks. Tumor growth is monitored daily by the same investigators, and tumor size is measured weekly. The tumor volume (mm3) is calculated as the tumor length (mm) × tumor width (mm)2/2. All animals are sacrificed on day 22 after treatment, and all animals survive during this period. Between-group differences in tumor growth are analyzed by two-way ANOVA.
References

[1]. Maillard MP, et al. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther. 2002 Sep;302(3):1089-95.

[2]. Xuan H, et al. Inhibition or deletion of angiotensin II type 1 receptor suppresses elastase-induced experimental abdominal aortic aneurysms. J Vasc Surg. 2017 Apr 20. pii: S0741-5214(17)30100-3.

[3]. Torika N, et al. Intranasal telmisartan ameliorates brain pathology in five familial Alzheimer's disease mice. Brain Behav Immun. 2017 Apr 3.

[4]. Aswar U, et al. Telmisartan attenuates diabetes induced depression in rats. Pharmacol Rep. 2017 Apr;69(2):358-364.

[5]. Fujihara S, et al. The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo. Oncotarget. 2017 Jan 31;8(5):8536-8549.
Density 1.2±0.1 g/cm3
Boiling Point 771.9±70.0 °C at 760 mmHg
Melting Point 261-263°C
Molecular Formula C33H30N4O2
Molecular Weight 514.617
Flash Point 420.6±35.7 °C
Exact Mass 514.236877
PSA 72.94000
LogP 7.73
Vapour Pressure 0.0±2.8 mmHg at 25°C
Index of Refraction 1.667
Storage condition Hygroscopic, -20°C Freezer, Under Inert Atmosphere
Water Solubility insoluble
Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Hazard Codes Xi: Irritant;
Risk Phrases R36/37/38
Safety Phrases S22-S24/25
RIDADR NONH for all modes of transport
WGK Germany 2

Chemsrc provides CAS#:144701-48-4 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 144701-48-4 | Chemsrc address: https://m.chemsrc.com/en/baike/832350.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved